TAKEDA SELECTS LEXICON GENETICS' HYPERTENSION TARGET FOR DEVELOPMENT IN RESEARCH ALLIANCE

Lexicon Genetics Incorporated (LEXG) announced that Takeda Pharmaceutical Company Limited has selected LG474 for therapeutic development. LG474 is a target that was discovered by Lexicon in its Genome5000 program.

Therapeutics Daily (http://www.therapeuticsdaily.com/news/article.cfm?contentValue=849469&contentType=sentryarticle&channelID=26)